The goal of the most recent 7th edition of the AJCC Cancer Staging Manual for gastric and esophageal cancer is to harmonize tumors arising from the distal esophagus to gastric cardia, including management of gastroesophageal junction (GEJ)-type tumors. The treatment of complex tumor types is best guided by a staging classification that reliably groups patients according to prognosis and therapy. The development of effective staging classifications is based on the analysis of large databases, ideally composed of patients that are consistently and accurately staged and treated, to derive accurate staging groups. Many challenges exist to developing a solid staging system for this area, because improved understanding of gastric, esophageal, and GEJ tumors has shown that this is a heterogeneous disease with varying outcomes depending on tumor location and type. Developing a system to adequately address these issues is an evolving target that will continue to require refinement and reconsideration as further data and analysis emerge. Therefore, this article elucidates the key features of this most recent staging system and outlines the changes and how they impact the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines) for Gastric and Esophageal Cancer.
Rice TW, Blackstone EH, Rusch VW. 7th Edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010;17:1721–1724.
Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophageal junction—classification, pathology and extent of resection. Dis Esophagus 1996;9:173–182.
Shaheen NJ, Sharma P, Overholt BF. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277–2289.
Fujita H, Sueyoshi S, Yamana H. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 2001;25:424–431.
Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538–543.
Hofstetter WL. Lymph node dissection in esophageal cancer. Current therapies in thoracic and cardiovascular surgery. In: Yang SC, Cameron DE, eds. Philadelphia, PA: Mosby, Inc.; 2004:360–363.
Rizk N, Venkatraman E, Park B. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006;132:1374–1381.
Strong VE, Song KY, Park CH. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010;251:640–646.
Mezhir JJ, Shah MA, Jacks L. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients, Ann Surg Oncol 2010;17:3173–3180.
Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1038 patients. Ann Surg 2000;232:362–371.
Sarela AI, Miner TJ, Karpeh MS. Clinical outcomes with laparoscopic stage M1 unresected gastric adenocarcinoma. Ann Surg Onc 2006;243:189–195.
Cooper JS, Guo MD, Herskovic A. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–1627.